Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-YL)phenethyl)guanidine is a synthetic small molecule belonging to the class of benzene and substituted derivatives. It features a guanidine group linked via an ethylene bridge to a phenyl ring substituted with a boron-containing dioxaborolane moiety. The compound is primarily referenced in chemical and pharmacological databases as an experimental or research molecule; there are no approved therapeutic indications or established mechanisms of action reported in public sources. Its structure suggests potential for use as a molecular probe or intermediate in medicinal chemistry research[1][9][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenethyl)guanidine.